Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Current Oncology Reports|October 19, 2023
Advances in Treatment of Waldenström MacroglobulinemiaEric Durot, Cécile Tomowiak
British Journal of Haematology|February 16, 2023
Born in the UK: A registry to improve and broadcast knowledge on Waldenström macroglobulinaemiaEric Durot, Alain Delmer
Clinical Nuclear Medicine|March 27, 2020
18FDG PET/CT in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg TypeSébastien Dejust, David Morland, Eric Durot, et al.
Medicine|February 4, 2022
Cerebellum/liver index in pretherapeutic 18F-FDG PET/CT as a predictive marker of progression-free survival in follicular lymphoma treated by immunochemotherapy and rituximab maintenanceFrançois Godard, Eric Durot, Carole Durot, et al.
Clinical Case Reports|August 28, 2018
Skeletal involvement of hairy cell leukemiaEric Durot, Anne Quinquenel, Jean-Charles Kleiber, et al.
European Journal of Haematology|November 1, 2014
Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter studyEric Durot, Anne-Sophie Michallet, Stéphane Leprêtre, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 4, 2025
Descriptive analysis of the efficacity of R-GEMOX /R-IE/R-CEPP in patients with relapsed/refractory (R/R) transplant-ineligible diffuse large B-cell lymphoma (DLBCL)Baptiste Fulbert, Théo Vincent, Justine Clarenne, et al.
Hematological Oncology|April 10, 2020
Hypercalcemia at diagnosis of diffuse large B-cell lymphoma is not uncommon and is associated with high-risk features and a short diagnosis-to-treatment intervalAnne-Cécile Gauchy, Lukshe Kanagaratnam, Anne Quinquenel, et al.
Hematology/Oncology Clinics of North America|May 28, 2023
Evaluation and Management of Disease Transformation in Waldenström MacroglobulinemiaDipti Talaulikar, Cécile Tomowiak, Elise Toussaint, et al.
Journal of Cancer Research and Clinical Oncology|July 5, 2022
Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphomaGwladys Claustre, Coralie Boulanger, Frédéric Maloisel, et al.
Pageof 6